Keyword Analysis & Research: crispr therapeutics
Keyword Research: People who searched crispr therapeutics also searched
Search Results related to crispr therapeutics on Search Engine
-
Home | CRISPR Therapeutics
https://crisprtx.com/
WEBLearn more about our programs. We have established a diverse portfolio across a broad range of disease areas including hemoglobinopathies, oncology, diabetes and cardiovascular disease. View Pipeline.
DA: 53 PA: 33 MOZ Rank: 59
-
CRISPR Therapeutics - Wikipedia
https://en.m.wikipedia.org/wiki/CRISPR_Therapeutics
WEBCRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. [2] [3] The company has approximately 500 employees and has offices in Zug ...
DA: 96 PA: 69 MOZ Rank: 27
-
Vertex and CRISPR Therapeutics Announce US FDA… | CRISPR Therapeutics
https://crisprtx.com/about-us/press-releases-and-presentations/vertex-and-crispr-therapeutics-announce-us-fda-approval-of-casgevy-exagamglogene-autotemcel-for-the-treatment-of-sickle-cell-disease
WEBCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA.
DA: 57 PA: 67 MOZ Rank: 56
-
Pipeline | CRISPR Therapeutics
https://crisprtx.com/pipeline
WEBExa-cel, a CRISPR/Cas9 gene-edited therapy arising out of our collaboration with Vertex Pharmaceuticals Incorporated, has now been approved in some countries for certain eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. Vertex is the manufacturer and exclusive license holder of exa-cel.
DA: 4 PA: 99 MOZ Rank: 36
-
CRISPR/Cas9 therapeutics: progress and prospects - Nature
https://www.nature.com/articles/s41392-023-01309-7
WEBJan 16, 2023 · CRISPR/ Cas9 is a highly effective gene-editing tool that is widely used in the scientific community. 6 The CRISPR/Cas9 system evolved naturally in bacteria and archaea as a defense...
DA: 7 PA: 55 MOZ Rank: 64
-
The First Crispr Medicine Is Now Approved in the US | WIRED
https://www.wired.com/story/the-first-crispr-medicine-is-now-approved-in-the-us/
WEBDec 8, 2023 · The US Food and Drug Administration today approved a first-of-its kind medical treatment that uses Crispr gene editing. Called Casgevy, the therapy is intended to treat patients with sickle...
DA: 1 PA: 95 MOZ Rank: 37
-
The world’s first CRISPR therapy is approved: who will receive it?
https://www.nature.com/articles/d41587-023-00016-6
WEBNov 21, 2023 · The UK’s regulator has approved the world’s first CRISPR–Cas9 gene editing therapy, which aims to cure sickle cell disease and transfusion-dependent β-thalassemia. Casgevy (exagamglogene...
DA: 43 PA: 48 MOZ Rank: 12
-
OVERVIEW | CRISPR Therapeutics
http://ir.crisprtx.com/
WEBCRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results. View All. Upcoming Events & Recent Presentations. There are currently no events scheduled. Jan 2024. 42nd Annual J.P. Morgan Healthcare Conference Presentation. Nov 2023. AHA 2023 (CTX310) Nov 2023. AHA 2023 (CTX320) Oct 2023.
DA: 6 PA: 83 MOZ Rank: 92
-
CRISPR Therapeutics Announces Updates to Immuno-Oncology …
https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-announces-updates-immuno-oncology-pipeline
WEBDec 4, 2023 · ZUG, Switzerland and BOSTON, Dec. 04, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today provided an update on its immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T cell product ...
DA: 6 PA: 61 MOZ Rank: 31
-
CRISPR Therapeutics Highlights Strategic Priorities and 2024 …
https://ir.crisprtx.com/news-releases/news-release-details/crispr-therapeutics-highlights-strategic-priorities-and-2024
WEBJan 8, 2024 · ZUG, Switzerland and BOSTON, Jan. 08, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today highlighted its strategic priorities and 2024 outlook as the Company enters its next phase of growth.
DA: 24 PA: 89 MOZ Rank: 69
